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ABSTRACT: Despite the promising features of liposomes as brain drug delivery vehicles, it remains uncertain how they
influence the brain uptake in vivo. In order to gain a better fundamental understanding of the interaction between liposomes
and the blood−brain barrier (BBB), it is indispensable to test if liposomes affect drugs with different BBB transport properties
(active influx or efflux) differently. The aim of this study was to quantitatively evaluate how PEGylated (PEG) liposomes
influence brain delivery of diphenhydramine (DPH), a drug with active influx at the BBB, in rats. The brain uptake of DPH after
30 min intravenous infusion of free DPH, PEG liposomal DPH, or free DPH + empty PEG liposomes was compared by
determining the unbound DPH concentrations in brain interstitial fluid and plasma with microdialysis. Regular blood samples
were taken to measure total DPH concentrations in plasma. Free DPH was actively taken up into the brain time-dependently,
with higher uptake at early time points followed by an unbound brain-to-plasma exposure ratio (Kp,uu) of 3.0. The encapsulation
in PEG liposomes significantly decreased brain uptake of DPH, with a reduction of Kp,uu to 1.5 (p < 0.05). When empty PEG
liposomes were coadministered with free drug, DPH brain uptake had a tendency to decrease (Kp,uu 2.3), and DPH was found
to bind to the liposomes. This study showed that PEG liposomes decreased the brain delivery of DPH in a complex manner,
contributing to the understanding of the intricate interactions between drug, liposomes, and the BBB.
KEYWORDS: nanocarrier, liposome, blood-brain barrier, brain uptake, microdialysis, diphenhydramine
■ INTRODUCTION
The presence of the blood−brain barrier (BBB) poses a huge
challenge for efficient drug delivery to the central nervous
system (CNS). The use of nanocarriers (e.g., liposomes,
nanoparticles) as drug delivery vehicles may provide
opportunities to enhance the uptake of drugs across the
BBB.1−3 However, it remains unclear how nanocarriers
influence the BBB transport of payload in vivo. Moreover,
given that the transport of drugs at the BBB can be dominated
by either active influx or active efflux, it is uncertain whether
brain uptake of drugs with different BBB transport properties
can be affected differently when they are nanoencapsulated.
To answer these questions, a pharmacokinetic (PK)
evaluation separating the released drug from the drug
remaining in the nanocarrier is of great importance. Micro-
dialysis plays an important role in this regard, providing unique
Received: June 12, 2018
Revised: August 22, 2018
Accepted: October 30, 2018
Published: October 30, 2018
Article
pubs.acs.org/molecularpharmaceuticsCite This: Mol. Pharmaceutics 2018, 15, 5493−5500
© 2018 American Chemical Society 5493 DOI: 10.1021/acs.molpharmaceut.8b00611























































































and quantitative information, as it allows the different in vivo
processes to be separated by measuring the released, unbound
drug concentrations in both brain and blood over time
together with regular blood sampling for total drug
concentrations in plasma.4 Thus, the impact of nanocarrier
on the BBB transport of drugs can be specifically studied
without being confounded by potential blood contamination in
brain tissue. In two recent studies using microdialysis, we
showed that encapsulation in PEGylated (PEG) liposomes
could improve the brain uptake of both small molecule
(methotrexate) and peptide (DAMGO) payloads to different
extents.5,6 Methotrexate (MTX) and DAMGO demonstrate
active efflux at the BBB when administered as free drug, as
described by the unbound brain-to-plasma concentration ratio
(Kp,uu) of 0.1 and 0.05, respectively. After liposomal
encapsulation, their Kp,uu values were increased 3- and 2-fold,
respectively. Additional modeling analysis indicates that the
most likely reason for enhanced brain delivery of DAMGO is a
fusion of liposomes with the BBB cell membrane.7 This fusion
process may to some extent bypass the efflux transporters
responsible for the limited CNS drug access. However, in order
to thoroughly understand how liposomes interact with the
BBB, it is necessary to test other payload drugs with different
BBB transport properties, e.g., drugs with active influx at the
BBB, indicated by Kp,uu > 1.
If the nanocarrier could potentially lead to transporter
circumvention when they interact with the BBB, they would
probably not only neutralize the role of efflux transporters but
also influence influx transport, possibly decreasing brain
delivery of drugs with active uptake at the BBB. A recently
published microdialysis study has indicated that this hypothesis
may be valid by showing a reduced brain uptake of quetiapine
when the drug was loaded into lipid-core nanocapsules, with a
reduction in Kp,uu from 1.55 to 0.94.
8 Nevertheless, there is
currently no quantitative evidence suggesting that liposomes
behave similarly to nanocapsules.
To assess how influx drug transport at the BBB could be
influenced by liposomes, diphenhydramine (DPH) was
selected as a model compound. DPH was reported to have a
Kp,uu of 5.5, indicating that active influx dominates its transport
at the BBB.9 The active uptake of DPH into the brain is
mediated by the proton-coupled organic cation antiporter
system.10 DPH is also a compound that is suitable to study
with microdialysis because of the minimal sticking to tubing
and probes.9−12 In the present study, PEGylated liposomes
containing egg yolk phosphatidylcholine (EYPC) were
selected, since this formulation with high fluidity was suggested
to interact with the BBB more easily through the proposed
fusion mechanism, compared to a more rigid formulation.5
The aim of this study was to investigate the influence of
PEGylated liposomes on the uptake of DPH across the BBB in
vivo. For this purpose, quantitative microdialysis in blood and
striatum was performed together with regular blood sampling.
This enables simultaneous monitoring of the concentration−
time profiles of released, unbound DPH in both brain and
plasma, as well as total DPH in plasma. This study, combined
with the previous work on MTX and DAMGO,5,6 can provide
quantitative elucidation on how the liposomes potentially
affect the brain delivery of drugs with active influx or active
efflux, which helps the in-depth understanding of how
liposomes interact with the BBB.
■ MATERIALS AND METHODS
Materials. DPH hydrochloride (HCl) powder and
deuterated DPH (DPH-D3) solution (100 μg/mL) were
purchased from Sigma-Aldrich (Steinheim, Germany). EYPC
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-conju-
gated polyethylene glycol MW 2000 (mPEG2000-DSPE) were
obtained from Lipoid (Cham, Switzerland). Cholesterol was
purchased from Sigma-Aldrich (Zwijndrecht, The Nether-
lands). The Ringer solution, consisting of 145 mM NaCl, 0.6
mM KCl, 1.2 mM CaCl2, 1.0 mM MgCl2, and 0.1 mM ascorbic
acid in 2.0 mM phosphate buffer (pH 7.4), was prepared in-
house. Acetonitrile, ammonia, formic acid, and glacial acetic
acid were of analytical grade (Merck, Darmstadt, Germany).
The water was purified with a Milli-Q Academic system
(Millipore, Bedford, MA, USA).
Liposome Preparation and Characterization. PEG
liposomal DPH and empty PEG liposomes were prepared
using an ethanol injection method with a pre-insertion of
mPEG2000-DSPE. In short, 100 mM EYPC, 66 mM cholesterol,
and 8.7 mM mPEG2000-DSPE (5 mol %) were first dissolved in
absolute ethanol. Then, 9.6 mL of lipid mixture was mixed with
30.4 mL of a solution of 25 mg/mL DPH HCl in Milli-Q water
for the drug-loading liposomes or saline for the empty
liposomes at 60 °C. The produced liposomes were extruded
stepwise through 200/200 and 200/100 nm Whatman filters
(Instruchemie, Delfzijl, The Netherlands) to reduce and unify
particle size. Nonencapsulated DPH was removed by ultra-
filtration on a Cogent μScale Tangential Flow Filtration
System (Merck Millipore) using a Pellicon XL 50 Cassette
equilibrated with saline. The purified liposomes were sterile
filtered using 0.2 μm filters, and aliquots were stored at 4 °C
until further use.
After releasing the DPH from the liposomes with
acetonitrile, the encapsulated drug was quantified using an
HPLC-UV method. Briefly, chromatographic separation was
carried out on a Xbridge C18 column (150 mm × 4.6 mm, 3.5
μm) (Waters, CA, USA) using a Shimadzu 20A ultrafast liquid
chromatography system (Shimadzu, Kyoto, Japan) under
isocratic elution with a mobile phase consisting of acetoni-
trile:sodium dihydrogen phosphate (pH 3.5 adjusted with
glacial acetic acid) (40:60, v/v). The flow rate was 1 mL/min,
and the column temperature was set at 23 °C. The UV
wavelength for detection was set at 205 nm. The EYPC
concentrations in the liposome samples were analyzed using
HPLC with an evaporative light-scattering detector (ELSD)
(Alltech, Ridderkerk, The Netherlands). A Kinetex C18
column (150 mm × 4.6 mm, 2.6 μm, Phenomenex) was
used for analysis with the column temperature set to 45 °C.
The chromatographic separation was performed using a
gradient elution of 0−10% mobile phase A (0.1 M ammonium
acetate, pH 6.0) and mobile phase B (methanol) at a flow rate
of 1.5 mL/min, with the total run time being 20 min. The
nitrogen gas flow of the ELSD was set at 1.5 mL/min with a
temperature of 80 °C. A Malvern Zetasizer Nano ZS90
(Malvern Instruments, Worcestershire, UK) was used to
measure the size of the liposome.
In Vitro Drug Release. The in vitro stability of PEG
liposomal DPH in both phosphate-buffered saline (PBS) and
rat plasma was tested. For the experiment, 10 μL of liposome
solution was added into 40 μL of either PBS or rat plasma, and
the mixture was incubated at 37 °C for 48 h. Samples were
taken at 0, 1, 2, 4, 8, 24, and 48 h during the incubation. Each
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sample was first diluted with 100 μL of PBS before loading 100
μL of the diluted sample onto a Zebaspin desalting column
(Thermo Scientific, Rockford, IL, USA) pre-equilibrated with
PBS. After that, the encapsulated DPH in the purified sample
was released by adding 100 μL of acetonitrile. The
concentration of DPH was measured using the above-
mentioned HPLC-UV assay. The amount of liposome-
encapsulated DPH at each time point was presented as the
percentage of the initial value at time 0 (T0).
Animals and Surgery. The animal procedures and study
protocols were approved by the Uppsala Regional Animal
Ethics Committee, Uppsala, Sweden (C13/14). Male
Sprague−Dawley rats were purchased from Taconic (Lille
Skensved, Denmark). The rats were allowed to acclimatize for
7 days before the experiments in temperature- and humidity-
controlled conditions with a 12 h light/dark cycle and
unrestricted access to food and water. The rats weighed
245−285 g on the experimental day.
The rats were anesthetized through inhalation of 2.5%
isoflurane (Isoflurane Baxter, Baxter Medical AB, Kista,
Sweden), combined with 1.5 L/min oxygen and 1.5 L/min
nitrous oxide. The body temperature of the rats was kept at 38
°C by a CMA/150 temperature controlled heating pad (CMA,
Stockholm, Sweden). PE-50 cannulas (MicLev, Malmö,
Sweden) were inserted into the left and right femoral veins
for drug administration and the left femoral artery for blood
sampling. The cannulas were pretreated with 100 IU/mL
heparin in saline to avoid clotting. Then, a flexible CMA/20
microdialysis probe with a 20 kDa cutoff and 10 mm
polyarylethersulfone (PAES) membrane (CMA, Stockholm,
Sweden) was inserted into the right jugular vein to measure the
released, unbound DPH concentrations in blood and fixed to
the pectoral muscle by two sutures. For sampling in brain
interstitial fluid (ISF), a CMA/12 guide cannula was first
implanted into striatum through a stereotaxic instrument
(David Kopf Instruments, Tujunga, USA), with a position of
2.7 mm lateral and 0.8 mm anterior to the bregma and 3.8 mm
ventral to the brain surface. After having been fixed to the skull
with a screw and dental cement (Dentalon Plus Heraeus,
Germany), the guide cannula was cautiously substituted by a
CMA/12 microdialysis probe with a 20 kDa cutoff and 3 mm
PAES membrane (CMA, Stockholm, Sweden). All catheters
were passed subcutaneously to the posterior surface of the
neck. After surgery, the rats were individually placed in a
CMA/120 system for freely moving animals and were given 24
h for recovery before the experiments started.
Experimental Procedures. On the day of experiment,
microdialysis probes were constantly perfused with Ringer
solution containing 10 ng/mL DPH-D3 as the recovery
calibrator at a flow rate of 1 μL/min, using a CMA/100
precision infusion pump (CMA, Stockholm, Sweden). The
perfusion started 90 min before the start of the i.v.
administration. Fluorinated ethylene propylene tubing
(CMA, Stockholm, Sweden) were used as inlet and outlet
tubing. The in vivo recovery of the probe was individually
measured throughout the whole study period in accordance
with retrodialysis.13 Before and after sample collection, all
sampling vials were weighed to examine the flow through the
probe during the experiment.
To compare the PK profiles between PEG liposomal DPH
and free DPH, a 30 min short infusion regimen was used. For
the liposomal group (n = 8), the rats were intravenously
administered 4.5 mg/kg (150 μg/min/kg) of PEG liposomal
DPH through the left femoral vein, using a Harvard 22 pump
(Harvard Apparatus Inc., Holliston, MA). For the “free drug
group” (n = 7), rats received an intravenous administration of
free DPH in saline at the same dose as the PEG liposomal
DPH, as a reference administration. One rat in the free DPH
group was excluded due to a microdialysis sampling issue from
the brain probe. To more thoroughly understand the liposomal
influence on the PK profiles of DPH, a coadministration group
(n = 4) was additionally included, in which free DPH (4.5 mg/
kg) and empty PEG liposomes (same EYPC dose as PEG
liposomal DPH) were injected simultaneously into the left and
right venous catheters as a 30 min infusion, respectively. The
microdialysate fractions from brain ISF and blood were
collected in polypropylene vials (AgnThos, Lidingö, Sweden)
every 15 min (∼15 μL) after the start of the retrodialysis
period until 120 min after the start of the infusion, and then
every 30 min (∼30 μL) for 4 h. The midpoint time in each
collection interval was used to plot the concentration−time
curve. Blood samples (∼200 μL) were withdrawn into
preheparinized polypropylene tubes before the infusion started
and at 10, 20, 30, 45, 60, 90, 120, 240, and 360 min after the
start of the infusion. After immediate centrifugation at 10000
rpm (7200g) for 5 min, the plasma was transferred to clean
polypropylene tubes. All samples were stored at −20 °C until
analysis.
Sample Analysis. An ultra performance liquid chromatog-
raphy-tandem mass spectrometry (UPLC-MS/MS) method
was used for quantifying DPH and DPH-D3 in microdialysate
and plasma. For sample preparation, 50 μL of plasma was
precipitated with 150 μL of acetonitrile containing 100 ng/mL
DPH-D3 as the internal standard (IS). After being vortexed
and centrifugated for 3 min at 13 000 rpm, a volume of 10 μL
of the supernatant was further diluted with 500 μL of the
mixture of mobile phase A and B (90/10; v/v). Five microliters
was then injected onto the UPLC-MS/MS system. An aliquot
of a 10 μL microdialysis sample was transferred to the injection
vial containing 90 μL of the same mobile phase mixture, before
injecting 5 μL of the diluted microdialysate onto the UPLC-
MS/MS system.
Chromatographic separation was carried out on an
ACQUITY BEH C18 column (50 mm × 2.1 mm, 1.7 μm)
protected by an ACQUITY BEH C18 guard column (10 mm
× 2.1 mm, 1.7 μm) (Waters, CA, USA) using a Waters
ACQUITY UPLC system (Waters, CA, USA). Mobile phase A
consisted of 90% 5 mM ammonium formate buffer (pH 3.4)
and 10% acetonitrile, and mobile phase B consisted of 90%
acetonitrile and 10% 5 mM ammonium formate buffer (pH
3.4). The gradient elution started at 10% B for 0.5 min, then
increased linearly to 40% B in 0.5 min, and maintained at 40%
B for 1.5 min, before returning to the initial condition for
equilibration. The flow rate was 0.3 mL/min, and the total run
time was 3 min. A Quattro Ultima triple quadrupole mass
spectrometer was used for the MS/MS detection (Waters,
Milford, MA, USA), and MassLynx software version 4.1
(Waters, Milford, MA, USA) was utilized for data acquisition
and processing. The detection of DPH and DPH-D3 was
performed in a positive electrospray mode using multiple
reaction monitoring transitions of 256.2 → 167.0 for DPH and
259.2 → 167.0 for DPH-D3. The standard curve with a range
of 1−5000 ng/mL DPH was used for plasma samples. For the
microdialysis samples, the standard curve for DPH-D3 ranged
from 0.1 to 20 ng/mL. The standard curves of DPH were 1−
500 ng/mL for the samples from the free drug group and 0.1−
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50 ng/mL for the samples from the liposomal group. Using 1/
x2 weighting, the coefficient of determination (R2) was higher
than 0.99 for all the standard curves. The quality controls were
accurate and precise in all runs with a coefficient of variation
being lower than 15% .
Data Analysis. No adsorption of DPH and DPH-D3 to
microdialysis probes and tubing was observed. The in vivo







where Ccalibrator,in is the concentration of DPH-D3 in the
microdialysis perfusate determined from triplicates before and
after the experiment, and Ccalibrator,out is the average
concentration of DPH-D3 in the collected dialysate during
the whole experiment.
The probe recoveries were stable throughout the experi-
ments. The average recovery was 0.37 ± 0.05 and 0.85 ± 0.06
for the brain and the blood probes, respectively.
The unbound concentration (Cu) of DPH in blood and






where Cdialysate is the concentration of DPH in the collected
microdialysis samples, and recovery is the individual average
measurement from either the brain or blood probe.
The PK parameters of total plasma concentration of DPH
were estimated on the basis of noncompartmental analysis.
The clearance (CL) and volume of distribution at steady state






















where R0 is the rate of infusion of free or PEG liposomal DPH,
and T is the duration of the infusion. The area under total
plasma concentration versus time curve (AUC0→∞) and the
area under the first moment versus time curve (AUMC0→∞)
were calculated using the linear trapezoid method. The residual
areas for AUC0→∞ and AUMC0→∞ were calculated as Clast/λz
and Clasttlast/λz + Clast/λz
2, respectively, where Clast is the
concentration measured at the last sampling point, and λz is the
terminal rate constant estimated from the slope of the 3 last
concentrations observed. The terminal half-life (t1/2) was
calculated as ln(2)/λz.
The unbound fraction of DPH in plasma ( f u) after the
infusion of free DPH was calculated as f u = AUCu,plasma/
AUCtot,plasma, where AUCu,plasma and AUCtot,plasma represent the
area under the unbound drug plasma concentration, calculated
from microdialysis sampling, and the area under the total
plasma concentration versus time curves, respectively. The
ratio of unbound to total DPH in plasma after the infusion of
PEG liposomal DPH was also calculated.
The brain uptake of DPH after administering free or








where the area under the unbound brain concentration
(AUCu,brain) and the area under the unbound plasma
concentration (AUCu,plasma) versus time curves were calculated
in two periods (0−60 min and 60−360 min) separately, using
the trapezoid method.
All data are presented as mean values ± standard deviation
(SD). GraphPad Prism version 7.03 for Windows (GraphPad
Software, San Diego CA, USA) was used for the statistical
analysis. The PK parameters of total DPH in plasma (CL, Vss,
and terminal t1/2) among the three groups were compared
using one-way ANOVA followed by Turkey’s multiple
comparison test. The Kp,uu values of DPH in the three groups
during the 0−60 and 60−360 min periods were compared
using a two-way ANOVA followed by Turkey’s multiple
comparisons test. A p < 0.05 was considered to be statistically
significant for all tests.
■ RESULTS
The average size of PEG liposomal DPH and empty PEG
liposomes were 83.6 ± 0.5 and 90.0 ± 0.5 nm, with a
polydispersity index of 0.11 ± 0.01 and 0.05 ± 0.01,
respectively. Both formulations were comparable in EYPC
contents. The encapsulation yielded a DPH concentration of
0.71 mg/mL in the liposomes. After incubation in either PBS
or rat plasma, an instability of PEG liposomal DPH was
observed (Figure 1). When incubated in PBS, the liposomes
were relatively stable for 24 h. At 48 h, 68% of DPH remained
encapsulated relative to the value at T0. A faster drug release
was observed when the liposomes were incubated in plasma,
with 33% remaining in the liposomes at 48 h.
The concentration−time profiles for DPH after the 30 min
i.v. infusion of free DPH, PEG liposomal DPH, or free DPH +
empty PEG liposomes are shown in Figure 2. In all groups,
biphasic PK profiles were observed for total DPH in plasma.
Compared to the free DPH group (Figure 2A), the PEG
liposomal DPH resulted in a faster initial decline and a slower
elimination phase in plasma (Figure 2B). Thus, the liposomal
encapsulation significantly prolonged the terminal t1/2. Total
plasma CL as well as Vss were significantly decreased relative to
Figure 1. In vitro release of PEG liposomal DPH in PBS and rat
plasma at 37 °C (n = 3).
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administering free DPH (Table 1). When free DPH was
coadministered with empty PEG liposomes, a slower
elimination process was also observed (Figure 2C) compared
to administering free drug alone. The coadministration of
empty liposomes significantly reduced the total plasma CL and
extended the terminal t1/2 of DPH (Table 1).
The unbound fraction of DPH in plasma after admin-
istration of free drug was 0.25 ± 0.05. This value was
significantly decreased in the coadministration group (Table
1), indicating that DPH binds to the liposomes. After
administration of PEG liposomal DPH, the total plasma
exposure was on average 286 ± 100 times higher than that of
the unbound DPH.
The unbound drug concentration in brain was higher than
that in plasma throughout the whole sampling period after
administration of free DPH, clearly confirming active uptake of
DPH at the BBB. However, the Cu,brain/Cu,plasma changed with
time from initially very high values (>10) to stabilizing at
around 3 (Figures 2A and 3A). This was also the case after
PEG liposomal DPH administration, although with the Cu,brain/
Cu,plasma decreasing even more after the first hour, as clearly
seen in Figures 2B and 3A. A similar pattern was also found
when empty liposomes were given together with free DPH
(Figures 2C and 3A), with the Cu,brain/Cu,plasma being between
that from the other two groups. This was the reason for
calculating the Kp,uu values in two separate periods (0−60 and
Figure 2. Concentration−time profiles of total DPH in plasma (filled circles), unbound DPH in plasma (open circles), and brain (open triangles)
after 30 min i.v. infusion of 4.5 mg/kg of (A) free DPH (n = 7), (B) PEG liposomal DPH (n = 8), or (C) free DPH + empty PEG liposomes (n =
4). Data are expressed as mean ± SD.
Table 1. Estimated PK Parameters of DPH in Rats after the Administration of Free DPH, PEG Liposomal DPH, or Free DPH
+ Empty PEG Liposomesa
administration groups
parameters free DPH PEG liposomal DPH free DPH + empty liposomes
terminal t1/2 (min) 59.7 ± 5.3 207 ± 9.0
** 123.4 ± 39.5**
CL (mL/min/kg) 123 ± 16 31.6 ± 3.7** 90.2 ± 32.3*
Vss (L/kg) 5.2 ± 1.0 2.6 ± 0.5
** 7.1 ± 4.0
f u or AUCu,plasma/AUCtot,plasma 0.25 ± 0.05 0.0039 ± 0.0014 0.09 ± 0.02
**
Kp,uu (0−60 min) 5.4 ± 0.7 5.4 ± 1.0 4.9 ± 2.0
Kp,uu (60−360 min) 3.0 ± 0.6 1.5 ± 1.2* 2.3 ± 0.6
aThe calculation of terminal t1/2, CL, and Vss are based on total plasma concentrations. Data are presented as mean ± SD.
*p < 0.05 compared to
the free DPH group. **p < 0.01 compared to the free DPH group.
Figure 3. (A) Unbound brain-to-plasma concentration ratio over time after 30 min i.v. infusion of free DPH, PEG liposomal DPH, or free DPH +
empty PEG liposomes. Data are expressed as mean ± SD, n = 4−8. (B) Unbound brain-to-plasma exposure ratio (Kp,uu) divided into the periods
0−60 and 60−360 min. *p < 0.05 between free DPH and PEG liposomal DPH during the 60−360 min period; ##p < 0.01 indicates significant
difference between the two periods. n = 4−8.
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60−360 min) (Figure 3B). In all three groups, the Kp,uu values
during 60−360 min were significantly lower than those during
the first 60 min (p < 0.01, Table 1 and Figure 3B). Comparing
the Kp,uu values among different groups showed that it was 3.0
± 0.6 after free DPH administration vs 1.5 ± 1.2 after PEG
liposomal DPH (p < 0.05, Table 1 and Figure 3B). The
average Kp,uu from the coadministration group was found to be
between 1.5 and 3, with no significant differences from either
the free DPH or PEG liposomal DPH group (Table 1 and
Figure 3B).
Individual plasma and brain concentration−time curves are
depicted in Figure S1. For the free DPH group, the curves in
plasma and brain were parallel, and brain concentrations in all
animals showed active uptake (Figure S1A). It was clearly
observed in 7 out of 8 animals in the liposomal DPH group
that the unbound brain profile declined faster than in plasma in
the early phase, and thereafter stabilized (Figure S1B). In the
coadministration group, the unbound and total plasma curves
deviated from each other from around 120 min after the start
of infusion (Figure S1C).
■ DISCUSSION
When developing liposome-based strategies to improve drug
delivery into the brain, the importance of understanding how
the payload itself is transported at the BBB is often underrated.
Having seen the positive impact of liposomes on the brain
delivery of drugs with active efflux at the BBB,5,6 one may
assume that the liposomal encapsulation would increase the
brain uptake of all drugs at the BBB, thus having more
opportunities to achieve targeted delivery and improved effect.
Our present study has shown that this wish may not be
fulfilled.
This article shows that the brain uptake of DPH with active
influx at the BBB is reduced after encapsulation in PEG-EYPC
liposomes, with a significantly smaller Kp,uu of 1.5 vs 3.0 when
administering the free drug. A reduction in brain uptake was
also observed in the study of quetiapine after nano-
encapsulation.8 Combined with our previous findings that
certain types of PEG liposomes can improve the brain delivery
of drugs with active efflux at the BBB,5,6 it seems that liposomal
encapsulation can influence BBB transport of drugs in different
directions depending on how the drug interacts with the BBB.
To be noted is that in our earlier study of MTX, only one of
two liposomal formulations were able to increase brain uptake,
indicating that in vivo delivery of drugs in liposomes is not a
unified process.5 For drugs with active influx (Kp,uu > 1),
liposomal encapsulation does not seem to be a good solution if
the purpose is to further increase the brain uptake, although
examples are still sparse.8 Therefore, it is of crucial importance
to be aware of the basic BBB transport features of the drug
intended to be encapsulated.
Interestingly, it seems that the coadministration of empty
PEG liposomes together with free DPH can also decrease the
brain uptake of DPH, although the reduction was smaller than
that from PEG liposomal DPH, reflected by a Kp,uu between
1.5 and 3.0. A similar free drug + empty liposomes group was
also included in a previous study in order to examine if
glutathione pegylated liposomes themselves increased brain
delivery of DAMGO by influencing BBB function. The
absence of difference in Kp,uu compared with administering
free DAMGO excluded this possibility.6 However, the decrease
in Kp,uu from 3.0 to 2.3 observed here does not necessarily
suggest that empty PEG liposomes themselves can actually
alter BBB function by inhibiting influx transporters. In fact,
when empty liposomes were administered simultaneously with
free DPH, the decreased unbound fraction of DPH and
deviation between unbound and total plasma PK curves during
the later period indicate a potential drug binding to the
liposomes. These liposomes may instead interact with the BBB
in a similar way as the DPH-encapsulated liposomes, which
may explain the reduction of Kp,uu compared to free drug
administration. Regardless of the effect on BBB transport, the
DPH binding to PEG liposomes was in itself an interesting
finding, indicating another possible in vivo drug and liposome
interaction. This finding can only be observed with the current
study design when administering both free drug and free drug
+ empty liposomes and with unbound and total plasma drug
concentrations measured separately.
Combining the present results with earlier in vivo results of
MTX and DAMGO, it could be speculated if liposomal
encapsulation is able to hinder transporter function.5,6 Both
MTX and DAMGO have active efflux at the BBB, and their
transport into the brain was improved when encapsulated into
liposomes. For DPH with active uptake at the BBB, the
opposite was found with a decreased uptake after encapsula-
tion. This was also the case for quetiapine.8 Thus, it seems as if
transporter function is reduced independent of direction.
However, when administering empty liposomes together with
free DAMGO, no influence was observed on the brain uptake
of DAMGO.6 Therefore, more studies are required to further
elucidate the intricate interactions among drugs, liposomes,
and the BBB transporters responsible for active influx or efflux
of drugs.
The presence of a biphasic PK profile of total DPH in
plasma with a fast decline in the early period suggests that a
part of the encapsulated DPH was released early in vivo, which
correlates with the in vitro observations. The biexponential PK
profile is quite different from the behavior of MTX in the same
formulation.5 However, this is not uncommon for PEG
liposomal formulations, as reported in other studies.16,17
Moreover, the terminal t1/2 for PEG liposomal DPH (around
3.5 h) is still within the reported range of the half-lives of PEG
liposomes (from 2 to 24 h).18
The Kp,uu of DPH showed a dramatic decrease from 14 to 3
within the first hour after free DPH administration, followed
by a relatively constant behavior thereafter. The average values
of Kp,uu in the two periods were actually similar to the results
from a previous study where Kp,uu was 5.5 during the constant
infusion period, followed by a decrease to approximately 3 in
the elimination phase after the infusion stopped.9 Earlier in
vitro results have suggested that DPH was actively transported
into the brain in a rapid and saturable manner.9,19 However,
saturation of uptake might be expected to occur with
increasing unbound concentration in plasma. What we
observed in the two studies is the opposite, with rather a
time-influence than a direct concentration influence. We do
not at the present time have an explanation to this
phenomenon.
During the first hour after administration of PEG liposomal
DPH, a similar drastic decrease was observed for Kp,uu, with no
early difference in the average Kp,uu compared to the free drug
group. However, after this period, the Kp,uu decreased
significantly more than after free DPH administration and to
values that indicate dominating passive transport, i.e., values
close to unity. We speculate that the absence of liposomal
influence during the initial period may be associated with the
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early drug release from the liposomes. Therefore, the Kp,uu
during the second period may be a better indicator reflecting
how DPH is transported at the BBB with and without
liposomal encapsulation. This is because an equilibrium
between unbound brain and plasma concentrations was
reached during this period, indicated by a stable Kp,uu in
both groups. Therefore, on the basis of the Kp,uu in the 60−360
min period, we conclude that PEG liposomal encapsulation
reduced the brain uptake of DPH. Our findings emphasize the
importance of understanding how the payload itself is
transported at the BBB before designing and developing any
nanocarrier-based strategy aiming at improving delivery of
drugs into the CNS.
■ CONCLUSIONS
In the present study, we were able to provide in vivo
quantitative evidence on how PEG liposomes influence the
brain uptake of DPH by using microdialysis. Compared with
free DPH administration, the encapsulation in PEG liposomes
significantly reduced DPH uptake into the brain. The
coadministration with empty PEG liposomes also showed a
tendency to decrease the transport of DPH at the BBB. These
results, together with previous findings on MTX and DAMGO,
give a better fundamental understanding of how PEG
liposomes influence the BBB transport of cargoes in different
directions. Our observations suggest that the in vivo BBB
transport property of the payload is a key factor affecting the
outcome of liposomal brain delivery. Therefore, this needs to
be considered in the early stage of design and development of
liposomal strategies for the treatment of CNS diseases.
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